Cargando…
Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination
BACKGROUND: Bisdemethoxycurcumin (BDMC), a stable bioactive ingredient in curcuminoids, is associated with various antitumor functions, such as proliferation inhibition, metastasis suppression and apoptosis induction, in many cancer types. However, the mechanism of BDMC in hepatocellular carcinoma (...
Autores principales: | Qiu, Chengjiang, Liu, Kairui, Zhang, Sheng, Gao, Simin, Chen, Weirun, Li, Dateng, Huang, Youxing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062405/ https://www.ncbi.nlm.nih.gov/pubmed/32184568 http://dx.doi.org/10.2147/DDDT.S231814 |
Ejemplares similares
-
Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020) -
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt
por: Lim, Jae Hyang, et al.
Publicado: (2012) -
Truncation of the Deubiquitinating Domain of CYLD in Myelomonocytic Cells Attenuates Inflammatory Responses
por: Tsagaratou, Ageliki, et al.
Publicado: (2011) -
Syndecan-4 negatively regulates antiviral signalling by mediating RIG-I deubiquitination via CYLD
por: Lin, Wei, et al.
Publicado: (2016) -
Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
por: Bekas, Nikolaos, et al.
Publicado: (2023)